• Doctors Wanted

    SALARIED GP ASSISTANT REQUIRED North County Dublin

    Permanent GP assistant with an interest in female health required for established Medical Teaching Practice in North County Dublin.

     Fully computerised (Socrates), with friendly and committed practice team. Part or full time hours available.

    Register your interest at info@salus.ieClosing date 19/04/2017. 

  • Training

    IRISH ASSOCIATION of SEXUAL and REPRODUCTIVE HEALTH CARE PROFFESIONALS (IASRHCP)

    MASTER CLASS April 8, 2017 8.30 am – 1.00 pm Alexander Hotel, 41-47 Fenian St, Dublin 2

    Co reg no. Ireland 130502

    8.30am to 9.00 am Registration and coffee
    9.30am to 10.00am Female Genital Mutilation an Irish Perspective - Dr Caitriona Henchion, Medical Director, I.F.P.A.
    10.00am to 10.30am Vulval Pathology
    Dr Cliodhna Murphy, Consultant Gynaecologist, Tallaght
    10.30am to 11.00am Vaccination Uptake - Dr Mc Conkey
    11.00am to 11.15am Morning Break
    11.15am to 11.45am The Transgender Question – what we need to know - Dr Fiona Martyn, Consultant Gynaecologist, Tallaght, Scheme N.M.H.
    12.00pm to 12.30pm The 10 minute Workshop
           Topics: Screening for STI
                      Vulval skin conditions
                      Ring Pessaries
                      Copper Coil fittings
    12.30pm – 1.00pm AGM close

    Registration Fee 50.00 Euro
    Payment on the day or by Paypal.ie to iasrhcp@gmail.com
    Info contact Dr Mary Short 01 2783870
    CPD points applied for

  • Partnership Available

    GP PARTNERSHIP OPPORTUNITY CORK

    For a well established and thriving GMS/ Private Practice based in the Primary Care Centre, Charleville, Co. Cork.

    Modern purpose built premises with Admin/Secretarial/Nursing support and onsite pharmacy.
    Member of SouthDoc.
    If interested please call 063-81783 or email magscondon1@gmail.com.

  • Miscellaneous

    Tynan Pianos Rathmines

    Showroom Condition

    Pianos of Quality
    Grands * Uprights

    Tynan Pianos Rathmines
    Tel. 01 4977807/ 4963587
    See www.tynanpianos.com

  • Doctors Wanted

    GP required Dublin 14.

    Part-time, with an interest in women’s healthcare, to join a high quality, long established 4 doctor practice.

    Please send cover letter with CV to rregan@iol.ie

  • Practice Nurse

    Practice Nurse, Dun laoghaire

    Practice Nurse Required for a fully computerised general practice working on a full-time or part-time basis.

     Experience in Phlebotomy, Childhood and Adult Vaccinations, Women’s Health, Cervical Screening. Occupational Health. Experience an advantage.
    CV to the Practice Manager, Harbour Health 1-2 Lower Glenageary Road, Dún Laoghaire, CoDublin, email info@harbourhealth.ie

  • Golf and Sports

    Killeen Castle Golf Club, Co Meath

    2017 Membership Now Available

    Call David Leech on 01 6893000

    davidleech@killeencastle.com
    www.killeencastle.com

    A Jack Nicklaus Signature Course

    Phone 01 6893000

    Email davidleech@killeencastle.com

    Website www.killeencastle.com

  • Miscellaneous

    Trajenta API

    Prescribing Information for Trajenta

     

     T4/E/PI/10 

     

    Prescribing Information (Ireland) 

    TRAJENTA® (Linagliptin) 

    Film-coated tablets containing 5 mg linagliptin. Indication: Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as: monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment; combination therapy in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control. Dose and Administration: 5 mg once daily. If added to metformin, the dose of metformin should be maintained and linagliptin administered concomitantly. When used in combination with a sulphonylurea or with insulin, a lower dose of the sulphonylurea or insulin, may be considered to reduce the risk of hypoglycaemia. Renal impairment: no dose adjustment required. Hepatic impairment: pharmacokinetic studies suggest that no dose adjustment is required for patients with hepatic impairment but clinical experience in such patients is lacking. Elderly: no dose adjustment is necessary based on age however, clinical experience in patients > 80 years of age is limited and caution should be exercised when treating this population. Paediatric population: the safety and efficacy of linagliptin in children and adolescents has not yet been established. No data are available. Take the tablets with or without a meal at any time of the day. If a dose is missed, it should be taken as soon as possible but a double dose should not be taken on the same day. Contraindications: Hypersensitivity to the active substance or to any of the excipients. Warnings and Precautions: Linagliptin should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. Caution is advised when linagliptin is used in combination with a sulphonylurea and/or insulin; a dose reduction of the sulphonylurea or insulin may be considered. Acute pancreatitis: In post-marketing experience of linagliptin there have been spontaneously reported adverse reactions of acute pancreatitis. Patients should be informed of the characteristic symptoms of acute pancreatitis. If pancreatitis is suspected, Trajenta should be discontinued; if acute pancreatitis is confirmed, Trajenta should not be restarted. Caution should be exercised in patients with a history of pancreatitis. Interactions: Linagliptin is a weak competitive and a weak to moderate mechanism-based inhibitor of CYP isozyme CYP3A4, but does not inhibit other CYP isozymes. It is not an inducer of CYP isozymes. Linagliptin is a P-glycoprotein substrate and inhibits P-glycoprotein mediated transport of digoxin with low potency. Based on these results and in vivo interaction studies, linagliptin is considered unlikely to cause interactions with other P-gp substrates. The risk for clinically meaningful interactions by other medicinal products on linagliptin is low and in clinical studies linagliptin had no clinically relevant effect on the pharmacokinetics of metformin, glibenclamide, simvastatin, warfarin, digoxin or oral contraceptives (please refer to Summary of Product Characteristics for information on clinical data). Fertility, pregnancy and lactation: Avoid use during pregnancy. A risk to the breast-fed child cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from linagliptin therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. No studies on the effect on human fertility have been conducted for linagliptin. Undesirable effects: Adverse reactions reported in patients who received linagliptin 5 mg daily as monotherapy or as add-on therapies (frequencies identified from pooled analysis of placebo-controlled studies) in clinical trial and from post-marketing experience. The adverse reactions are listed by absolute frequency. Frequencies are 

    T4/E/PI/10 

    defined as very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (<1/10,000) ornot known (cannot be estimated from the available data).Verycommon: hypoglycaemia(combination with/add-on to metformin and sulphonylurea). Common: lipaseincreased (monotherapy;combination with/add-on to metformin;combination with/add-on to metformin and sulphonylurea; combination with/add-on to insulin;combination with/add-on to metformin and empagliflozin). Uncommon:nasopharyngitis (monotherapy; combination with/add-on to metformin;combination with/add-on to insulin); hypersensitivitye.g. bronchial hyperreactivity(monotherapy;combination with/add-on to metformin;combination with/add-on to metformin and sulphonylurea; combination with/add-on to insulin); cough (monotherapy;combination with/add-on to metformin; combination with/add-on to insulin);pancreatitis (combination with/add-on to insulin);constipation (combination with/add-on to insulin);rash (monotherapy; combination with/add-onto metformin; combination with/add-onto metformin and sulphonylurea; combination with/add-onto insulin); amylase increased (combination with/add-onto metformin; combination with/add-on to metformin and sulphonylurea; combination with/add-on to metformin and empagliflozin). Rare: angioedema (monotherapy; combination with/add-onto metformin; combination with/add-onto metformin and sulphonylurea; combination with/add-onto insulin); urticaria (monotherapy; combination with/add-onto metformin; combination with/add-onto metformin and sulphonylurea; combination with/add-onto insulin);amylase increased (monotherapy). Not known:nasopharyngitis (combination with/add-on to metformin and sulphonylurea;combination with/add-on to metformin and empagliflozin); hypersensitivitye.g. bronchial hyperreactivity (combination with/add-on to metformin and empagliflozin); cough (combination with/add-on to metformin and sulphonylurea;combination with/add-on to metformin and empagliflozin); pancreatitis (monotherapy;combination with/add-on to metformin; combination with/add-on to metformin and sulphonylurea;combination with/add-on to metformin and empagliflozin);bullouspemphigoid (monotherapy; combination with/add-onto metformin; combinationwith/add-onto metformin and sulphonylurea; combination with/add-onto insulin); amylase increased(combination with/add-on to insulin). Prescribers should consultthe Summary of Product Characteristicsfor further information on side effects.Packsizes:28 tablets. Legalcategory:POM. MAnumber:EU/1/11/707/003.MarketingAuthorisationHolder:BoehringerIngelheimInternational GmbH, D-55216 Ingelheim am Rhein, Germany. Prescribersshould consult the Summary ofProduct Characteristics for full prescribing information. Additional information isavailable on requestfromBoehringer Ingelheim Ireland Ltd,The CrescentBuilding, Northwood, Santry, Dublin 9.PreparedinFebruary 2017.

    T4/E/PI/10

    Prescribers should consult the Summary of Product Characteristics for full prescribing information. Additional information is available on request from Boehringer Ingelheim Ireland Ltd, The Crescent Building, Northwood, Santry, Dublin 9. Prepared in February 2017.

     

     

     J1/E/PI/10 

     

    Prescribing Information - Ireland 

    JENTADUETO® (linagliptin and metformin hydrochloride) 

    Film-coated tablets containing 2.5 mg linagliptin and 850 mg metformin hydrochloride or 2.5 mg linagliptin and 1,000 mg metformin hydrochloride. Indication: Jentadueto is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: in patients inadequately controlled on their maximally tolerated dose of metformin alone; in combination with other medicinal products for the treatment of diabetes, including insulin, in patients inadequately controlled with metformin and these medicinal products; in patients already being treated with the combination of linagliptin and metformin as separate tablets. Dose and Administration: Adults with normal renal function (glomerular filtration rate (GFR)≥ 90 ml/min): The dose should be individualised based on the patient’s current regimen, effectiveness and tolerability, not exceeding the maximum recommended daily dose of 5 mg linagliptin plus 2,000 mg metformin hydrochloride. Patients inadequately controlled on maximal tolerated dose of metformin monotherapy: the usual starting dose should provide linagliptin 2.5 mg twice daily (5 mg total daily dose) plus the current metformin dose. Patients switching from co-administration of linagliptin and metformin: Initiate at the dose of linagliptin and metformin already being taken. Patients inadequately controlled on dual combination of the maximal tolerated dose of metformin and a sulphonylurea: The dose should provide linagliptin 2.5 mg twice daily (5 mg total daily dose) and a metformin dose similar to the dose already being taken. When linagliptin plus metformin hydrochloride is used in combination with a sulphonylurea, a lower dose of the sulphonylurea may be required to reduce the risk of hypoglycaemia. Patients inadequately controlled on dual combination with insulin and the maximal tolerated dose of metformin: The dose should provide linagliptin 2.5 mg twice daily (5 mg total daily dose) and a metformin dose similar to the dose already being taken. When linagliptin plus metformin hydrochloride is used in combination with insulin, a lower dose of insulin may be required to reduce the risk of hypoglycaemia. Elderly: As metformin is excreted by the kidney, use with caution as age increases. Monitoring of renal function is necessary. Exercise caution in patients 80 years and older as clinical experience in this age group is limited. Renal impairment: Assess GFR before initiating treatment and at least annually thereafter, or more frequently (e.g. every 3-6 months) in patients at an increased risk of further progression of renal impairment and in the elderly. Review factors that may increase lactic acidosis risk before considering initiation in patients with GFR<60 ml/min. If no adequate strength of Jentadueto is available, use individual monocomponents instead of the fixed dose combination. For full details prescribers should consult the Summary of Product Characteristics. Hepatic impairment: Not recommended. Clinical experience in patients with hepatic impairment is lacking. Paediatric population: Safety and efficacy in children and adolescents (aged 0 to 18 years) have not been established. No data are available. Taking Jentadueto: To be taken twice daily with meals. All patients should continue their diet with an adequate distribution of carbohydrate intake during the day. Overweight patients should continue their energy-restricted diet. If a dose is missed, it should be taken as soon as the patient remembers. However, a double dose should not be taken at the same time (the missed dose should be skipped). Contraindications: Hypersensitivity to the active substances or to any of the excipients; any acute metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis); diabetic pre-coma; severe renal failure (GFR < 30 ml/min); acute conditions with the potential to alter renal function such as dehydration, severe 

    J1/E/PI/10 

    infection, shock;disease which may cause tissue hypoxia (especiallyacute disease, orworsening of chronic disease) such as decompensated heart failure,respiratory failure, recent myocardial infarction, shock; hepatic impairment, acutealcohol intoxication,alcoholism.WarningsandPrecautions:Should notbe used in patients with type 1 diabetes.Caution is advised when Jentadueto is used in combination with asulphonylureaand/or insulindue to increased incidence ofhypoglycaemia.Acute worsening of renal function causes metformin accumulation and increases the risk oflactic acidosis.Temporarily discontinue treatment in case ofdehydration (severe diarrhoea or vomiting, fever or reduced fluid intake).Initiate products that can acutelyimpair renal function (e.g. antihypertensives, diuretics andnon-steroidal anti-inflammatory drugs(NSAIDs)) with caution. Inform patients and/or caregivers of therisk of lactic acidosis. If lactic acidosis is suspected the patient should stop takingJentadueto and seek immediate medicalattention. Intravascular administration ofiodinated contrast agents may result in metformin accumulation and increased risk oflactic acidosis.Discontinue treatmentprior to or at the time of the imagingprocedure. Restart afterat least 48hours, provided that renalfunction isre-evaluated and found to be stable. Assess GFRbefore initiating treatment and regularly thereafter(see Dose and Administration).Temporarily discontinue treatmentin the presence of conditionsthat alter renal function.Patients with heart failure are more at risk of hypoxia andrenalimpairment.In patients with stable chronic heart failureuse Jentaduetowithregular monitoring of cardiac and renal function. Discontinue treatmentat the time ofsurgeryundergeneral, spinal or epidural anaesthesia.Restart therapynoearlier than48 hours following surgery orresumption of oral nutritionand provided that renalfunction isre-evaluated and found to be stable. Apatient with previously well controlled type 2 diabetes on Jentadueto who develops laboratory abnormalities orclinical illness (especiallyvague and poorly defined illness) should be evaluated promptly forevidence ofketoacidosis or lacticacidosis. Ifacidosis of either formoccurs, stop treatmentimmediately andinitiateother appropriate corrective measures.There have beenspontaneously reported adverse reactions of acute pancreatitiswithlinagliptin. If pancreatitis is suspected, Jentadueto should bediscontinued; ifconfirmed, treatmentshould not be restarted.Patients should be informed of thecharacteristic symptoms of acute pancreatitis.Exercise cautionin patients with ahistory of pancreatitis.Interactions:Combination requiring precautions for use:glucocorticoids (given by systemic and local routes), beta-2-agonists, and diuretics. More frequent blood glucose monitoring should be performed, especially at thebeginning of treatment with such medicinal products.If necessary,adjustthe dose ofJentaduetoduring therapywith the other medicinal product and on itsdiscontinuation;products which may increase therisk of lactic acidosise.g. NSAIDs, includingselective cyclo-oxygenase (COX)IIinhibitors, ACE inhibitors, angiotensin IIreceptor antagonists and diuretics.Monitor renal function closely when starting orusing such products.Concomitant usenot recommended:Alcohol; iodinated contrastagents. Fertility,pregnancyandlactation:Jentadueto should not be used duringpregnancy. If the patient plans to become pregnant, or if pregnancy occurs,discontinue treatment and switch to insulin treatment as soon aspossible in order to lower the risk offoetal malformations associated with abnormal blood glucose levels. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain fromJentadueto therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. No studies on theeffect on human fertilityhave been conducted forJentadueto. Undesirableeffects:Frequencies are defined asvery common (≥1/10), common (≥1/100to <1/10), uncommon (≥1/1,000 to <1/100), rare(≥1/10,000 to <1/1,000), very rare

    J1/E/PI/10

    Patients with heart failure are more at risk of hypoxia and renal impairment. In patients with stable chronic heart failure use Jentadueto with regular monitoring of cardiac and renal function. Discontinue treatment at the time of surgery under general, spinal or epidural anaesthesia. Restart therapy no earlier than 48 hours following surgery or resumption of oral nutrition and provided that renal function is re-evaluated and found to be stable. A patient with previously well controlled type 2 diabetes on Jentadueto who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis. If acidosis of either form occurs, stop treatment immediately and initiate other appropriate corrective measures. There have been spontaneously reported adverse reactions of acute pancreatitis with linagliptin. If pancreatitis is suspected, Jentadueto should be discontinued; if confirmed, treatment should not be restarted. Patients should be informed of the characteristic symptoms of acute pancreatitis. Exercise caution in patients with a history of pancreatitis. Interactions: Combination requiring precautions for use: glucocorticoids (given by systemic and local routes), beta-2-agonists, and diuretics. More frequent blood glucose monitoring should be performed, especially at the beginning of treatment with such medicinal products. If necessary, adjust the dose of Jentadueto during therapy with the other medicinal product and on its discontinuation; products which may increase the risk of lactic acidosis e.g. NSAIDs, including selective cyclo-oxygenase (COX) II inhibitors, ACE inhibitors, angiotensin II receptor antagonists and diuretics. Monitor renal function closely when starting or using such products. Concomitant use not recommended: Alcohol; iodinated contrast agents. Fertility, pregnancy and lactation: Jentadueto should not be used during pregnancy. If the patient plans to become pregnant, or if pregnancy occurs, discontinue treatment and switch to insulin treatment as soon as possible in order to lower the risk of foetal malformations associated with abnormal blood glucose levels. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Jentadueto therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. No studies on the effect on human fertility have been conducted for Jentadueto. Undesirable effects: Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare 

    J1/E/PI/10 

    (< 1/10,000) and not known (cannot be estimated from the available data). Adverse reactions reported with the fixed dose combination: Common: diarrhoea; lipase increased. Uncommon: nasopharyngitis; hypersensitivity e.g. bronchial hyperreactivity; cough; decreased appetite; nausea; vomiting; rash; pruritus; blood amylase increased. Rare: angioedema; urticaria. Not known: pancreatitis, bullous pemphigoid. Adverse reactions known to occur with each active substance given singly but which have not been seen in clinical trials with Jentadueto, may occur during treatment with this medicinal product. Additional adverse reactions reported when linagliptin and metformin were combined with sulphonylurea: very common: hypoglycaemia. Additional reactions reported when linagliptin and metformin were combined with insulin: Uncommon: constipation; liver function disorders. Additional information on individual components: Adverse reactions previously reported with one of the individual active substances may be potential adverse reactions with Jentadueto, even if not observed in clinical trials. Linagliptin: All identified adverse reactions of linagliptin monotherapy are also described for Jentadueto. Metformin: Known adverse reactions that were not reported in patients who received Jentadueto. Very common: abdominal pain. Common: taste disturbance. Very rare: lactic acidosis; vitamin B12 deficiency; hepatitis; skin reactions. Prescribers should consult the Summary of Product Characteristics for further information on side effects. Pack sizes: 2.5 mg/850 mg 56 tablets; 2.5 mg/1,000 mg 56 tablets. Legal category: POM. MA numbers: 2.5 mg/850 mg (56 tablets) EU/1/12/780/005; 2.5 mg/1,000 mg (56 tablets) EU/1/12/780/019. 

    (<1/10,000)and not known (cannot be estimated from the available data).Adverse reactions reported with the fixed dose combination:Common: diarrhoea;lipase increased.Uncommon: nasopharyngitis;hypersensitivity e.g. bronchialhyperreactivity;cough; decreased appetite; nausea; vomiting;rash;pruritus; blood amylase increased.Rare:angioedema; urticaria. Not known: pancreatitis, bullouspemphigoid.Adverse reactions known to occur with each active substancegiven singlybut which have not been seen in clinical trials with Jentadueto, mayoccurduring treatment with this medicinal product.Additional adverse reactions reportedwhen linagliptinand metformin were combined with sulphonylurea:very common: hypoglycaemia.Additional reactions reported when linagliptin and metformin werecombined with insulin:Uncommon: constipation;liver function disorders. Additionalinformation on individual components:Adverse reactions previously reported with one of the individual active substances may be potential adverse reactionswith Jentadueto, even if not observed in clinical trials.Linagliptin:All identifiedadversereactions of linagliptin monotherapy are also described for Jentadueto. Metformin:Known adverse reactionsthat were not reported in patients who received Jentadueto. Very common: abdominal pain. Common: taste disturbance. Very rare: lacticacidosis; vitamin B12 deficiency;hepatitis; skinreactions.Prescribers should consultthe Summary of Product Characteristicsfor further information on side effects.Packsizes:2.5mg/850mg56tablets; 2.5mg/1,000mg56tablets.Legalcategory:POM.MAnumbers:2.5mg/850mg (56tablets)EU/1/12/780/005; 2.5 mg/1,000mg (56tablets) EU/1/12/780/019.MarketingAuthorisationHolder:BoehringerIngelheim International GmbH, D-55216 Ingelheim am Rhein, Germany.Prescribersshould consult the Summary of Product Characteristics for full prescribinginformation.Additional information is available on requestfrom Boehringer Ingelheim Ireland Ltd, The Crescent Building, Northwood, Santry, Dublin 9.PreparedinFebruary 2017.

    J1/E/PI/10

    Prescribers should consult the Summary of Product Characteristics for full prescribing information. Additional information is available on request from Boehringer Ingelheim Ireland Ltd, The Crescent Building, Northwood, Santry, Dublin 9. Prepared in February 2017.

  • International Jobs

    GP Fellowships UK

    Recently Qualified or More Experienced GP?

    Looking for a role that will develop your skills mix in line with a more integrated health economy?

    MatchMedics, in conjunction with Primary Care People, are partnering with Clinical Commissioning Groups in NHS England to offer 1, 2 and 3 year post qualification GP fellowships with start dates in 2017.

    You will work with local GP practices with additional sessions in other healthcare settings. Funded education sessions through UK universities and private study form a key part of the fellowship.

    See more on this unique career opportunity at www.matchmedics.com/GPFellowship

    Full support on the application process and registration will be provided.

    Do not delay - contact us today for full information pack and to register your interest.

    01 404 7611 / 087 927 6000

    www.matchmedics.com

    info@matchmedics.com

  • Practice Nurse

    Family based GP Practice in Castleknock Dublin 15 are recruiting a part time practice nurse

    to join our existing team. Two days per week - Wednesday and Thursdays from 8am-4pm.

    Experience essential and duties as per scope of GP Practice Nurse - phlebotomy, childhood
    vac’s,cryotherapy, cervical smears etc..
    Fully computerised using Health one software with admin support.


    CV for the attention of Lydia Clark to theparksmedicalcentre@gmail.com

  • Miscellaneous

    Shane O’Toole Specialist Medical Accountant & Lecturer - RCSI Institute of Leadership

    Now Offering - Outsourced Bookkeeping & Payroll

    2016 Company Returns due before ARD to keep Audit Exemption


    Please feel free to call 01 8013116/ email: info@doctorsaccountant.ie for help & support

  • Training

    John Fitzpatrick Irish Genitourinary Cancer Conference 2017

    6th – 7th April 2017 Aviva Stadium Conference Centre, Dublin

    REGISTRATION NOW OPEN!

    To view the conference programme & to register visit
    www.irishgenitourinaryconference2017.org

    For further information, please contact:
    Emer O’Connor at the conference secretariat Global Teamwork
    Email: emer@globalteamwork.ie
    Tel: +353 (01) 265 0001

  • Doctors Wanted

    GP REQUIRED DUBLIN 2

    Part-time/ full-time GP required for busy fully private practice in Dockland’s area.

    Happy work place with full support staff.
    Must be flexible re hours, excellent remuneration.

    Please send cover letter with up to date CV to ncollins@hanovermedical.ie

    Email ncollins@hanovermedical.ie

  • Practice Nurse

    PRACTICE NURSE, CORK

    A busy GP practice requires a part time nurse in Cork City.

    Role includes midwifery, smears, vaccinations, phlebotomy and all aspects of nursing care in General Practice. Previous experience is desirable but not essential.


    Replies to gpbishopstown@gmail.com

    Email gpbishopstown@gmail.com

  • Medical Practice - For Sale/To Let

    MEDICAL SUITES AVAILABLE, DUBLIN 2

    Medical Suites available in Clare Street Medical Centre, Dublin 2.

    Adjacent to the National Gallery – suitable for GP, Dermatologist, Sexual Health Clinic,
    Gynaecologist or any other medical discipline.
    Full medical planning permission approved.
    Large footfall, set to increase with completion of Luas – adjacent to Trinity College and
    Merrion Square. Rent & terms negotiable. Viewing essential.

    Please contact Mary Anne on 087 6394946.
    Letting by John Agar: 01 2137777/ 086 2562359.

    Phone 087 6394946

  • Practice Nurse

    Practice Nurse, Cork city

    A busy and dynamic GP practice in Cork City is looking to hire 2 part-time practice nurses.

    We are looking for nurses with prior experience and training in cervical smears, vaccinations
    and venepuncture. The role also involves administration, occupational medicine
    and other areas of interest are encouraged.
    Surgery hours are 8:30 - 17:00 Monday to Friday.

    Replies to corkcitygpsurgery@gmail.com

  • Consulting Rooms

    Clinical Rooms to rent above busy GP Practice

    on Kimmage Road West.

     Contact Bernadette Malone 086 8518183 for further details.

  • Doctors Wanted

    GP Assistant, Santry

    A vacancy has arisen for a GP Assistant/Sessional GP in OMNI PARK medical centre Santry. Ideally 3-5 sessions per week

    however I am flexible in relation to number of sessions.
    Pleasant shopping centre based practice. The practice is computerised with usual ancillary staff
    and full time practice nurse. No OOH or house calls required.
    Starting date is flexible.
    Please forward CV by email to: Gppractice579@gmail.com or for informal enquiry ring Jackie
    practice manager 086 8255935.

    Phone 086 8255935

    Email Gppractice579@gmail.com

  • Doctors Wanted

    GP Assistant required for Cork City Practice.

    Surgery fully computerised with full nursing, managerial and secretarial support.

    Eight-nine sessions per week with opportunity for long-term position/ partnership.

    Starting January 2017.

    CVs or enquiries to: meadowparksurgery@gmail.com or call 086 8558871.

  • Training

    Sexually Transmitted Infection Foundation Course (STIF) STIF Course

    Dates: 13th and 14th May 2017 Venue: Catherine Mc Auley Centre, 21 Nelson St, Dublin 7

    BASHH endorsed (British Association Sexual Health and HIV)

    Accredited by The Nursing and Midwifery Board of Ireland (NMBI)

    Recognized for CPD

    Target Audience

    Multidisciplinary-Doctors and Nurses from primary care, family planning, secondary care clinicians, ID and GUM NCCG’s, public health advisers, (who may encounter patients with STIs) who want an update on STIs.
    Aim of the course
    To equip participants with the basic knowledge, skills and attitudes for the effective management of STIs.

    By the end of the course you should be able to:
    Knowledge
    • describe the principles of STI service provision
    •recognise the issues relating to confidentiality, partner notification and treatment
    • demonstrate basic knowledge of the epidemiology and the factors involved in the transmission of STIs and how to prevent transmission
    • demonstrate basic knowledge of STIs, their presentation, diagnosis and managemet
    • indicate where and when to refer patients
    Skills
    • demonstrate competency, and feel comfortable, in taking a sexual history
    • demonstrate the skills necessary to inform patients about reducing their
    risk of sexual infections and risk of unplanned pregnancy
    • optimise care pathways for patients through improved links with local services (GUM, Sexual Health, Contraceptive
    • services, Psychosexual services, Microbiology, TOP services and Primary Care)
    Attitudes
    • demonstrate an appreciation of the lifestyle and circumstances of others and how this may reflect in their presentation and impact on their management.
    • recognise the range of human sexuality, lifestyles and culture and the impact this has on transmission/prevention counselling
    • demonstrate an understanding of how one’s personal beliefs could affect the consultation

    In addition we are now also oering the STIF course competency training upon request. This is additional
    clinical training for doctors and nurses. Training dates are agreed on a one on one basis.

    Course Director: Consultant Dr J Lambert, GUM and ID, Rotunda and Mater Hospitals and UCD School of Medicine.
    Course fee including lunch and Tea/Coffee for the day €360 with an early bird offer of €300 if booked more than 3months prior to the course

    Optional elearning available

    Course registration forms
    and further information can be obtained from:
    Gordana Avramovic, Catherine Mc Auley Education and Research Centre, 21 Nelson Street, Dublin 7
    Tel 01 716 4562 Email gavramovic@mater.ie

    Phone 01 716 4562

    Email gavramovic@mater.ie

  • Training

    The Mater Misericordiae University Hospital are delighted to invite you to the 2017 National

    Post-Exposure Prophylaxis (PEP) Conference on 26th April 2017 in the Rotunda Hospital Pillar Room.

    This conference will focus on HIV and other blood borne virus prevention including Needle Stick PEP, Community PEP, Sexual Assault
    PEP and High-Risk Sexual Encounter PEP, and will be focusing on the current status of PEP & PREP in Ireland.
    The Conference will be of interest to healthcare professionals and service providers including:
    • Infectious Diseases
    • Emergency Medicine
    • Occupational Health Professionals
    • Microbiologists
    • General Physicians
    • Ambulance Services
    • Dentists
    • Obstetricians and Gynecologists
    • Public Health Professionals
    • Pharmacists
    • Government and NGO representatives
    • Garda and Prison Doctors
    • STI and SATU Staff


    The total cost to attend this conference is €50 including lunch.

    To register, please send the €50 registration fee (non-refundable) made payable to The Mater Hospital along with your name and full contact details to Gordana Avramovic, Catherine Mc Auley Education and Research Centre, UCD-MMUH, 21 Nelson Street, Dublin 7 by Friday 21st April 2017.

    Scholarships are available for community.
    For more information, please telephone 01 716 4562 or email gavramovic@mater.ie.

    Phone 01 716 456

    Email gavramovic@mater.ie

  • Doctors Wanted

    Medsource.ie Quality Services for Medical Practices

    GP Locums

    Earn €65,000+ per year working 18 hours at weekends*
    Earn €40,000 per year working 12 hours midweek*

    GP Locums also required for Day Surgery

    Contact Helen or Jenny in MedSource
    046-9241533 / info@medsource.ie/www.medsource.ie
    * Weekends = 3 x 6 hours in OOH
    * Midweek = 3 x 4 hours in OOH

    Phone 046-9241533

    Email info@medsource.ie

    Website www.medsource.ie

  • Partnership Available

    GP PARTNERSHIP OPPORTUNITY

    Do you want to join a well established practice in South-West Dublin – 10 mins from the M50?

    2 Doctor practice – older partner retiring. You will be an assistant with a  view (fast tracked) to full partnership for the right candidate. Must have MICGP or equivalent.
    Retiring partner will facilitate easy transition.

    Email: tallaghtnewgp@gmail.com

    Email tallaghtnewgp@gmail.com

  • Holiday Resorts

    HOUSE RENTAL MARBELLA SPAIN.

    Between San Pedro and Puerto Banus - www.condesdeiza.com

    3 bed, 2 reception, 3 bathrooms, roof terrace with excellent views and basement.
    Beside Pool, gated. 5 min walk to Campana village, 15min to Puerto Banus.
    700 Euros per week except for July and August at 900 Euros per week.
    Nice development of town houses mostly with year round occupancy.
    Secured by 25% immediate payment.
    Email to bestiberia@hotmail.com or text to 086 814 4636.

    Phone 086 814 4636

    Email bestiberia@hotmail.com

    Website  www.condesdeiza.com

Medical Independent Poll

Do you believe Ireland will be tobacco-free by 2025 (smoking prevalence of less than 5%)?


Submit Poll
  • Search our Archives

  • Search
  • Latest from PharmacistCPD
  • Men's Health

    Erectile dysfunction

    This module reviews the diagnosis, investigations and treatment of Erectile Dysfunction (ED) as well as discussing the historical progression of implantable penile devices since their inception....

    Take Module